Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
University Hospital, Clermont-Ferrand
144 participants
Mar 5, 2026
OBSERVATIONAL
Conditions
Summary
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.
Eligibility
Inclusion Criteria7
- Cisgender women, premenopausal, aged 18 to 50 years.
- Cisgender men, aged 18 to 50 years.
- Diagnosed with migraine (according to ICHD-3 criteria).
- Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022).
- Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics).
- All routes of administration and all dosages.
- Affiliation with a social security system.
Exclusion Criteria2
- Patients under guardianship, curatorship, deprivation of liberty, or legal protection
- Pregnant and breastfeeding women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07177885